Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 4/2015

01-04-2015 | Research Paper

Growth pattern of colorectal liver metastasis as a marker of recurrence risk

Authors: R. L. Eefsen, P. B. Vermeulen, I. J. Christensen, O. D. Laerum, M. B. Mogensen, H. C. Rolff, G. G. Van den Eynden, G. Høyer-Hansen, K. Osterlind, B. Vainer, M. Illemann

Published in: Clinical & Experimental Metastasis | Issue 4/2015

Login to get access

Abstract

Despite improved therapy of advanced colorectal cancer, the median overall survival (OS) is still low. A surgical removal has significantly improved survival, if lesions are entirely removed. The purpose of this retrospective explorative study was to evaluate the prognostic value of histological growth patterns (GP) in chemonaive and patients receiving neo-adjuvant therapy. Two-hundred-fifty-four patients who underwent liver resection of colorectal liver metastases between 2007 and 2011 were included in the study. Clinicopathological data and information on neo-adjuvant treatment were retrieved from patient and pathology records. Histological GP were evaluated and related to recurrence free and OS. Kaplan–Meier curves, log-rank test and Cox regression analysis were used. The 5-year OS was 41.8 % (95 % CI 33.8–49.8 %). Growth pattern evaluation of the largest liver metastasis was possible in 224 cases, with the following distribution: desmoplastic 63 patients (28.1 %); pushing 77 patients (34.4 %); replacement 28 patients (12.5 %); mixed 56 patients (25.0 %). The Kaplan–Meier analyses demonstrated that patients resected for liver metastases with desmoplastic growth pattern had a longer recurrence free survival (RFS) than patients resected for non-desmoplastic liver metastases (p = 0.05). When patients were stratified according to neo-adjuvant treatment in the multivariate Cox regression model, hazard ratios for RFS compared to desmoplastic were: pushing (HR = 1.37, 95 % CI 0.93–2.02, p = 0.116), replacement (HR = 2.16, 95 % CI 1.29–3.62, p = 0.003) and mixed (HR = 1.70, 95 % CI 1.12–2.59, p = 0.013). This was true for chemonaive patients as well as for patients who received neo-adjuvant treatment.
Literature
1.
Kemeny N (2007) Presurgical chemotherapy in patients being considered for liver resection. Oncologist 12:825–839CrossRefPubMed
2.
Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244:254–259CrossRefPubMedCentralPubMed
3.
Muratore A, Ribero D, Viganos L (2011) Epidemiology and natural history; surgical treatment of colorectal liver metastases. Springer, Milan, pp 1–6
4.
Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM (2010) Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 59:1383–1388CrossRefPubMed
5.
Grossmann I, Doornbos PM, Klaase JM, de Bock GH, Wiggers T (2014) Changing patterns of recurrent disease in colorectal cancer. Eur J Surg Oncol 40:234–239CrossRefPubMed
6.
Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16:1311–1319CrossRefPubMed
7.
Sorbye H (2014) Recurrence patterns after resection of liver metastases from colorectal cancer. Recent Results Cancer Res 203:243–252CrossRefPubMed
8.
Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766CrossRefPubMedCentralPubMed
9.
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van CE, Scheithauer W, Gruenberger T (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016CrossRefPubMedCentralPubMed
10.
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van CE, Scheithauer W, Gruenberger T (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215CrossRefPubMed
11.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMed
12.
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019CrossRefPubMed
13.
Van CE, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haen G, Pinter T, Zaluski J, Zaluski J, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417CrossRef
14.
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van CE (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345CrossRefPubMed
15.
Van CE, Cervantes A, Nordlinger B, Arnold D (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 25:5643–5647
16.
Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77:1254–1262CrossRefPubMed
17.
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318CrossRefPubMedCentralPubMed
18.
Kohne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13:308–317CrossRefPubMed
19.
Vermeulen PB, Colpaert C, Salgado R, Royers R, Hellemans H, Van Den Heuvel E, Goovaerts G, Dirix LY, Van Marck E (2001) Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J Pathol 195:336–342CrossRefPubMed
20.
Van den Eynden GG, Bird NC, Majeed AW, Van LS, Dirix LY, Vermeulen PB (2012) The histological growth pattern of colorectal cancer liver metastases has prognostic value. Clin Exp Metastasis 29:541–549CrossRefPubMed
21.
Eefsen RL, Van den Eynden GG, Høyer-Hansen G, Brodt P, Laerum OD, Vermeulen PB, Christensen IJ, Wettergren A, Federspiel B, Willemoe GL, Vainer B, Osterlind K, Illemann M (2012) Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases. J Oncol 2012:907971CrossRefPubMedCentralPubMed
22.
Yamaguchi J, Komuta K, Matsuzaki S, Okudaira S, Fujioka H, Kanematsu T (2002) Mode of infiltrative growth of colorectal liver metastases is a useful predictor of recurrence after hepatic resection. World J Surg 26:1122–1125CrossRefPubMed
23.
Nagashima I, Oka T, Hamada C, Naruse K, Osada T, Muto T (1999) Histopathological prognostic factors influencing long-term prognosis after surgical resection for hepatic metastases from colorectal cancer. Am J Gastroenterol 94:739–743CrossRefPubMed
24.
Pinheiro RS, Herman P, Lupinacci RM, Lai Q, Mello ES, Coelho FF, Perini MV, Pugliese V, Andraus W, Cecconello I, D’Albuquerque LC (2014) Tumor growth pattern as predictor of colorectal liver metastasis recurrence. Am J Surg 207:493–498CrossRefPubMed
25.
Okano K, Yamamoto J, Kosuge T, Yamamoto S, Sakamoto M, Nakanishi Y, Hirohashi S (2000) Fibrous pseudocapsule of metastatic liver tumors from colorectal carcinoma. Clinicopathologic study of 152 first resection cases. Cancer 89:267–275CrossRefPubMed
26.
Nielsen K, Rolff HC, Eefsen RL, Vainer B (2014) The morphological growth patterns of colorectal liver metastases are prognostic for overall survival. Mod Pathol 27(12):1641–1648CrossRefPubMed
27.
Nystrom H, Naredi P, Berglund A, Palmqvist R, Tavelin B, Sund M (2012) Liver-metastatic potential of colorectal cancer is related to the stromal composition of the tumour. Anticancer Res 32:5183–5191PubMed
28.
Lunevicius R, Nakanishi H, Ito S, Kozaki K, Kato T, Tatematsu M, Yasui K (2001) Clinicopathological significance of fibrotic capsule formation around liver metastasis from colorectal cancer. J Cancer Res Clin Oncol 127:193–199CrossRefPubMed
29.
Couinaud C (1999) Liver anatomy: portal (and suprahepatic) or biliary segmentation. Dig Surg 16:459–467CrossRefPubMed
30.
Vandeweyer D, Neo EL, Chen JW, Maddern GJ, Wilson TG, Padbury RT (2009) Influence of resection margin on survival in hepatic resections for colorectal liver metastases. HPB 11:499–504CrossRefPubMedCentralPubMed
31.
Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715–722CrossRefPubMedCentralPubMed
32.
Angelsen JH, Horn A, Eide GE, Viste A (2014) Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival. World J Surg Oncol 12:127CrossRefPubMedCentralPubMed
33.
Mekenkamp LJ, Koopman M, Teerenstra S, van Krieken JH, Mol L, Nagtegaal ID, Punt CJ (2010) Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer 103:159–164CrossRefPubMedCentralPubMed
34.
Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ, Pahlman L, Sobrero A, Douillard JY (2007) Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 99:998–1003CrossRefPubMed
35.
Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med 9:e1001216CrossRefPubMedCentralPubMed
36.
Bancroft JD, Cook HC (1994) Connective tissue. In: Bancroft JD, Cook JC (eds) Manual of histological techniques and their diagnostic application. Churchill Livingstone, Edinburgh, pp 35–67
37.
Illemann M, Bird N, Majeed A, Laerum OD, Lund LR, Danø K, Nielsen BS (2009) Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 124:1860–1870CrossRefPubMed
38.
Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Sakamoto M, Fukuda H (1999) Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg 86:332–337CrossRefPubMed
39.
Ueno H, Mochizuki H, Hashiguchi Y, Hatsuse K, Fujimoto H, Hase K (2004) Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br J Surg 91:327–333CrossRefPubMed
40.
Grossniklaus HE (2013) Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture. JAMA Ophthalmol 131:462–469CrossRefPubMed
41.
Nakashima T, Kojiro M, Kawano Y, Shirai F, Takemoto N, Tomimatsu H, Kawasaki H, Okuda K (1982) Histologic growth-pattern of hepatocellular-carcinoma-relationship to orcein(hepatitis-B surface antigen)-positive cells in cancer-tissue. Hum Pathol 13:563–568CrossRefPubMed
42.
Stessels F, Van den Eynden G, Van der Auwera I, Salgado R, Van Den Heuvel E, Harris AL, Jackson DG, Colpaert CG, van Marck EA, Dirix LY, Vermeulen PB (2004) Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer 90:1429–1436CrossRefPubMedCentralPubMed
43.
Terayama N, Terada T, Nakanuma Y (1996) Histologic growth patterns of metastatic carcinomas of the liver. Jpn J Clin Oncol 26:24–29CrossRefPubMed
44.
Knijn N, de Ridder JA, Punt CJ, de Wilt JH, Nagtegaal ID (2013) Histopathological evaluation of resected colorectal cancer liver metastases: what should be done? Histopathology 63:149–156CrossRefPubMed
45.
Van den Eynden GG, van Dam PJ, Stroobants S, Dirix L, Vermeulen P (2014) Histopathological evaluation of resected colorectal cancer liver metastases: what should be done? Histopathology 64:315–316CrossRefPubMed
46.
Slesser AA, Georgiou P, Brown G, Mudan S, Goldin R, Tekkis P (2013) The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review. Clin Exp Metastasis 30:457–470CrossRefPubMed
47.
van der Pool AE, Lalmahomed ZS, Ozbay Y, de Wilt JH, Eggermont AM, Jzermans JN, Verhoef C (2010) ‘Staged’ liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome. Colorectal Dis 12:e229–e235CrossRefPubMed
48.
Ghiringhelli F, Hennequin A, Drouillard A, Lepage C, Faivre J, Bouvier AM (2014) Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study. Dig Liver Dis 46(9):854–858CrossRefPubMed
49.
Bova R, Kamphues C, Neuhaus P (2014) Puhl G [Impact of time of occurrence of liver metastases (synchronous vs. metachronous) on early postoperative outcome and long-term survival of colorectal cancer patients]. Zent Chir 139:220–225
50.
Dexiang Z, Li R, Ye W, Haifu W, Yunshi Z, Qinghai Y, Shenyong Z, Bo X, Li L, Xiangou P, Haohao L, Lechi Y, Tianshu L, Jia F, Xinyu Q, Jianmin X (2012) Outcome of patients with colorectal liver metastasis: analysis of 1613 consecutive cases. Ann Surg Oncol 19:2860–2868CrossRefPubMed
51.
Ng WW, Cheung YS, Wong J, Lee KF, Lai PB (2009) A preliminary analysis of combined liver resection with new chemotherapy for synchronous and metachronous colorectal liver metastasis. Asian J Surg 32:189–197CrossRefPubMed
52.
Tsai MS, Su YH, Ho MC, Liang JT, Chen TP, Lai HS, Lee PH (2007) Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 14:786–794CrossRefPubMed
53.
Landreau P, Drouillard A, Launoy G, Ortega-Deballon P, Jooste V, Come L, Faivre J, Facy O, Bouvier AM (2014) Incidence and survival in late liver metastases of colorectal cancer. J Gastroenterol Hepatol 30(1):82–85CrossRef
Metadata
Title
Growth pattern of colorectal liver metastasis as a marker of recurrence risk
Authors
R. L. Eefsen
P. B. Vermeulen
I. J. Christensen
O. D. Laerum
M. B. Mogensen
H. C. Rolff
G. G. Van den Eynden
G. Høyer-Hansen
K. Osterlind
B. Vainer
M. Illemann
Publication date
01-04-2015
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 4/2015
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-015-9715-4

Other articles of this Issue 4/2015

Clinical & Experimental Metastasis 4/2015 Go to the issue

Research Paper

MTBP inhibits migration and metastasis of hepatocellular carcinoma

Research Paper

Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis

Review

MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM-1/Src signaling triad

Research Paper

Tumour growth of colorectal rat liver metastases is inhibited by hepatic arterial infusion of the mTOR-inhibitor temsirolimus after portal branch ligation

Research Paper

Dietary soy isoflavones increase metastasis to lungs in an experimental model of breast cancer with bone micro-tumors

Research Paper

Dormancy and growth of metastatic breast cancer cells in a bone-like microenvironment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits